Sign in Subscribe
Pediatrics

Diagnostic Genomic Analysis Proves Prognostic in Adolescents and Young Adults with Acute Lymphoblastic Leukemia

Strategic Insights

— 1 min read

New research has shed light on the impact of genomics in an individual cohort of adolescents and young adults (AYA) patients with acute lymphoblastic leukemia (ALL) treated on a single protocol. The study, conducted by researchers at the South Australian Health and Medical Research Institute, aimed to describe the genomic drivers of ALL in an AYA cohort (ALL06) and assess the safety and efficacy of adapting a pediatric chemotherapy protocol in older patients. The findings reveal a strong correlation between adverse genomic risk and minimal residual disease (MRD) at the end of consolidation, translating to inferior overall and relapse-free survival.

Key Takeaways:

  • The study investigated the genomic drivers of ALL in an AYA cohort (ALL06) and found that 36 of 40 (90%) patients with B-ALL and 13 of 17 (76.5%) patients with T-ALL were classified according to genomic risk.
  • Genomic risk classification based on multiple assays, including messenger RNA sequencing, multiplex ligation-dependent probe amplification, immunophenotyping, and cytogenetics, showed a strong correlation with MRD at the end of consolidation.
  • Patients with adverse risk genomics who achieved negative MRD status had improved responses compared to those with persistent MRD.
  • Patients with standard-risk genomics had excellent responses regardless of MRD status, highlighting the importance of genomic risk classification in ALL treatment paradigms.
  • The study argues for the incorporation of genomic risk classification into future ALL treatment paradigms at the time of diagnosis and rigorous assessment of risk assignments in AYA patients.

Statistics:

  • 36 of 40 (90%) patients with B-ALL were classified according to genomic risk.
  • 13 of 17 (76.5%) patients with T-ALL were classified according to genomic risk.
  • 90% of B-ALL patients and 76.5% of T-ALL patients had a strong correlation between adverse genomic risk and MRD at the end of consolidation.
  • Patients with adverse risk genomics had inferior overall and relapse-free survival rates compared to those with standard-risk genomics.

Sources:

  • NewsRx. South Australian Health and Medical Research Institute Reports Findings in Acute Lymphoblastic Leukemia (Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol). Pediatrics Week. July 12, 2025; p 604.
  • Blood Neoplasia. Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol. 2024;2(1):100041.

Read more